The United Kingdom and the United States have established a important trade agreement that will preserve zero import taxes on British pharmaceutical products entering the US market.
The Terms of the Deal
As part of the deal, the UK has pledged to raise funding on medicines through the public health system. This commitment guarantees that tariffs on these vital exports will remain at zero for a period of the next three years.
This agreement comes after earlier warnings to dramatically increase import taxes on branded pharmaceutical products, with potential rates floated up to double the cost.
"This deal with the UK strengthens the international landscape for new treatments and introduces much-needed balance to American-British drug exports," an announcement said.
Trade Importance
Drugs represent one of the Britain's largest export categories to the US, which is by far the primary buyer for leading British pharmaceutical firms.
Trade data indicate that in the year leading up to September, the UK sold medicines valued at £11.1bn to the US. This figure represented 17.4% of British export trade in that span.
"This guarantee safeguards jobs, increases investment and paves the way for the UK to become a global hub for life sciences," a minister commented.
Specific UK Commitments
The deal involves several notable pledges from the UK:
- Price Threshold Increase: The UK will lift the cost ceiling at which it considers new medicines to be unaffordable by 25%.
- Increased NHS Spending: There is a target to raise overall health service expenditure on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Rebate Cap: The sum drug companies must return to the NHS to control costs will be restricted at 15%. Last year, refunds topped twenty percent.
Broader Context
The pact follows a protracted dispute between the drug companies and the UK government over drug pricing and approval rates.
These tensions were heightened by assertions that US consumers were charged significantly more for the same drugs than people in the other developed nations.
Over the last 18 months, several major manufacturing plans in the UK have been halted or cancelled, while multi-billion-dollar investments have been pledged toward US facilities.
One official publicly accepted that the NHS had to increase expenditure on medicines, noting that its budget allocation on drugs had shrunk as a share of its resources over the past decade.
